What combination regimens containing BCMA-directed bispecific antibodies are being evaluated for MM?
The Multiple Myeloma Hub spoke with Alexander Lesokhin, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What combination regimens containing B-cell maturation antigen (BCMA)-directed bispecific antibodies are being evaluated for multiple myeloma (MM)?
In this interview, Lesokhin discussed the range of combination regimens featuring a BCMA-directed bispecific antibody for MM, outlining the rationale for these strategies and noting that while BCMA bispecifics have shown high response rates in the relapsed/refractory setting outcomes can be further improved. Lesokhin reviewed…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.